Abstract 48P
Background
Sentinel lymph node biopsy (SLNB) in post-neoadjuvant chemotherapy (NACT) has demonstrated a higher false negative rate (FNR) compared to early breast cancer. This might result from a non-uniform pattern of tumour regression in SLN and Non-SLN within the axilla. SLNB can assess SLN alone by itself, but preoperative axillary ultrasound (AUS) can also determine the characteristics of Non-SLN. We studied whether axillary staging in post-NACT patients could be improved by combining AUS and SLNB to reduce false negative cases.
Methods
It was a single-centre, prospective study that was conducted between September 2020 and June 2022. All Post-NACT, clinically node-negative(cN0) patients who were scheduled for surgery were enrolled and underwent AUS. AUS normal node patients underwent SLNB using fluorescein and methylene blue followed by Axillary Lymph Node Dissection (ALND). We evaluated the AUS's Positive Predictive Value (PPV), Negative Predictive Value (NPV) and FNR in cN0 patients. The FNR of SLNB was calculated in patients who had cN0 and AUS normal nodes.
Results
cN0 was found in 62 patients out of 136 post-NACT patients.AUS had PPV and NPV of 90.6% and 76.6%, respectively. The FNR for AUS alone was 19.4% (7/36). Loss of fatty hilum was found to have a PPV of 89.3% and a sensitivity of 70%, making it the most reliable marker of nodal metastasis. Methylene blue allergy was observed in 1 patient. The FNR of SLNB was 8.6% (2/23) for the patients who had been selected for SLNB based on AUS normal nodes.
Conclusions
AUS alone or SLNB alone is insufficient to determine axilla node-negative status and can't omit ALND because each has a high FNR (>10%). If AUS findings are considered for selecting patients for SLNB, it reduces its FNR to below 10% and improves the accuracy of axillary staging in post-NACT patients.
Clinical trial identification
Clinical Trials Registry (India) number- CTRI/2020/10/028337.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract